VRDNHealthcare · BiotechnologyVRDN Stock Forecast: Viridian Therapeutics, Inc. Price Predictions for 2026-2027
The 17 Wall Street analysts covering Viridian Therapeutics, Inc. hold a median 12-month price target of $35 — +81.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 1 Aug 2026 — in the lower half.
VRDN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Viridian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (81): The share price has been relatively steady.
Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Viridian Therapeutics, Inc. — and when they’d sell — is the membership.
VRDN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VRDN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +81.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 June 2026 | Needham | Maintains | Buy | $32 → $34 |
| 30 June 2026 | RBC Capital | Maintains | Outperform | $34 → $35 |
| 30 June 2026 | Truist Securities | Maintains | Buy | $35 → $38 |
| 30 June 2026 | Wedbush | Maintains | Outperform | $32 → $43 |
| 29 June 2026 | Needham | Reiterates | Buy | $32 |
| 29 June 2026 | Wells Fargo | Upgrade | Overweight | $20 → $31 |
| 15 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 May 2026 | RBC Capital | Maintains | Outperform | — |
| 5 May 2026 | Needham | Reiterates | Buy | — |
| 21 Apr 2026 | Truist Securities | Maintains | Buy | — |
| 8 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 7 Apr 2026 | Goldman Sachs | Maintains | Buy | — |
| 7 Apr 2026 | RBC Capital | Maintains | Outperform | — |
| 2 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 31 Mar 2026 | Goldman Sachs | Maintains | Buy | — |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 31 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 31 Mar 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 30 Mar 2026 | Needham | Maintains | Buy | — |
| 11 Mar 2026 | Wedbush | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
VRDN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Viridian Therapeutics, Inc. (VRDN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −5.7×
- Price / sales
- 29.5×
- Price / book
- 3.8×
- EV / EBITDA
- −3.6×
Cheaper than 90% of US stocks
Cheaper than 7% of US stocks
Cheaper than 27% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- 95.8%
- Earnings growth (YoY)
- 95.8%
- Gross margin
- —
- Operating margin
- −82389.4%
- Net margin
- 0.0%
Higher than 93% of US stocks
Higher than 86% of US stocks
Higher than 1% of US stocks
Higher than 30% of US stocks
- Return on equity
- −58.1%
- Return on assets
- −33.3%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 13% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
VRDN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRDN appears on the weeks it earns a place.
Frequently asked questions about VRDN stock
What is the VRDN stock price forecast for 2026-2027?
The 17 Wall Street analysts covering Viridian Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $22 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VRDN stock a buy right now?
Of the 17 analysts covering Viridian Therapeutics, Inc., 17 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viridian Therapeutics, Inc. 43 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VRDN?
As at 1 Aug 2026, Viridian Therapeutics, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (81 of 100).
Will VRDN stock go up?
No one can know that. What the data says: the median 12-month target from 17 analysts implies +81.3% from the last close, and Ticker Nerd's factor model ranks Viridian Therapeutics, Inc. 43 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VRDN stock forecast for 2030?
No analyst covering Viridian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $50 over the next 12 months.
How has VRDN stock performed over the past year?
Viridian Therapeutics, Inc. returned +10.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Viridian Therapeutics, Inc. do?
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing best-in-class medicines for patients with autoimmune and rare diseases, particularly thyroid eye disease (TED).
About Viridian Therapeutics, Inc.
Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing best-in-class medicines for patients with autoimmune and rare diseases, particularly thyroid eye disease (TED). The company leverages expertise in antibody discovery and protein engineering to create differentiated therapeutic candidates targeting validated disease mechanisms. Its lead programs include veligrotug, a humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R) administered intravenously, currently in Phase 3 clinical trials (THRIVE and THRIVE-2) for active and chronic TED. Viridian is also advancing elegrobart (formerly VRDN-003), a next-generation subcutaneous IGF-1R antibody with half-life extension technology, in ongoing Phase 3 trials (REVEAL-1 and REVEAL-2) for TED. Additionally, the company develops an anti-thyroid-stimulating hormone receptor (TSHR) program for TED and Graves' disease, along with neonatal Fc receptor (FcRn) inhibitors such as VRDN-006 and VRDN-008 for multiple autoimmune conditions. Headquartered in Waltham, Massachusetts, and founded in 2006, Viridian Therapeutics plays a key role in addressing unmet needs in rare autoimmune therapies through innovative antibody-based treatments.
CEO Mr. Stephen F. Mahoney J.D., MBA · 252 employees · United States · https://www.viridiantherapeutics.com